Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
American gastroenterological association consensus development conference on the use of biologics in the treatment of inflammatory bowel disease, June 21-23, 2006.
Clark M, Colombel JF, Feagan BC, Fedorak RN, Hanauer SB, Kamm MA, Mayer L, Regueiro C, Rutgeerts P, Sandborn WJ, Sands BE, Schreiber S, Targan S, Travis S, Vermeire S. Clark M, et al. Among authors: rutgeerts p. Gastroenterology. 2007 Jul;133(1):312-39. doi: 10.1053/j.gastro.2007.05.006. Gastroenterology. 2007. PMID: 17631151
Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease.
D'Haens G, Feagan B, Colombel JF, Sandborn WJ, Reinisch W, Rutgeerts P, Carbonnel F, Mary JY, Danese S, Fedorak RN, Hanauer S, Lémann M; International Organization for Inflammatory Bowel Diseases (IOIBD) and the Clinical Trial Committee Clincom of the European Crohn's and Colitis Organisation (ECCO). D'Haens G, et al. Among authors: rutgeerts p. Gastroenterology. 2012 Dec;143(6):1461-9. doi: 10.1053/j.gastro.2012.09.031. Epub 2012 Sep 20. Gastroenterology. 2012. PMID: 23000597 Review.
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial.
Targan SR, Feagan BG, Fedorak RN, Lashner BA, Panaccione R, Present DH, Spehlmann ME, Rutgeerts PJ, Tulassay Z, Volfova M, Wolf DC, Hernandez C, Bornstein J, Sandborn WJ; International Efficacy of Natalizumab in Crohn's Disease Response and Remission (ENCORE) Trial Group. Targan SR, et al. Gastroenterology. 2007 May;132(5):1672-83. doi: 10.1053/j.gastro.2007.03.024. Epub 2007 Mar 21. Gastroenterology. 2007. PMID: 17484865 Clinical Trial.
Antibody responses in Crohn's disease.
Vermeire S, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Gastroenterology. 2004 Feb;126(2):601-4. doi: 10.1053/j.gastro.2003.12.020. Gastroenterology. 2004. PMID: 14762797 Review. No abstract available.
Novel biological strategies in inflammatory bowel diseases.
Vermeire S, Rutgeerts P. Vermeire S, et al. Among authors: rutgeerts p. Inflamm Bowel Dis. 2004 Feb;10 Suppl 1:S44-51. doi: 10.1097/00054725-200402001-00010. Inflamm Bowel Dis. 2004. PMID: 15168831 Review. No abstract available.
Medical treatment of inflammatory bowel diseases.
Van Assche G, Vermeire S, Rutgeerts P. Van Assche G, et al. Among authors: rutgeerts p. Curr Opin Gastroenterol. 2005 Jul;21(4):443-7. Curr Opin Gastroenterol. 2005. PMID: 15930985 Review.
727 results